Search results for "AEM"

showing 10 items of 1006 documents

Early ROS-mediated DNA damage and oxidative stress biomarkers in Monoclonal B Lymphocytosis

2012

Monoclonal B Lymphocytosis (MBL) is defined as asymptomatic monoclonal B-cell expansion characterised by a CLL-phenotype, but with less than 5 x 10(9)/I circulating cells. Reactive oxygen species (ROS)-mediated cell damage plays a critical role in the initiation of carcinogenesis as well as in malignant transformation. The goal of this study was to perform an analysis of the oxidative stress statuses of patients affected by MBL and chronic lymphocytic leukaemia (CLL). We examined peripheral blood and urine specimens from 29 patients with MBL, 55 with CLL and 31 healthy subjects. There was a significant increase in the occurrence of the mutagenic base 8-oxo-2'-deoxiguanosine (8-oxo-dG) in th…

8-Oxo-dGMaleChronic lymphocytic leukaemiaCancer ResearchF-2-isoprostanesTime FactorsLymphocytosisDNA damageLymphocytosisBiologyDinoprostmedicine.disease_causeAntioxidantsLipid peroxidationchemistry.chemical_compoundMalondialdehydemedicineHumansCell damageChromatography High Pressure LiquidAgedchemistry.chemical_classificationB-LymphocytesReactive oxygen speciesGlutathione DisulfideDeoxyguanosineMonoclonal B LymphocytosisGlutathioneMiddle AgedMalondialdehydemedicine.diseaseGlutathioneLeukemia Lymphocytic Chronic B-CellOxidative StressOncologychemistryOxidative stress8-Hydroxy-2'-DeoxyguanosineImmunologyDNA damageFemalemedicine.symptomReactive Oxygen SpeciesBiomarkersOxidative stressDNA DamageCancer Letters
researchProduct

Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1.

2014

The Pterogyne nitens (Fabaceae) tree, native to South America, has been found to produce guanidine alkaloids as well as bioactive flavonols such as kaempferol, quercetin, and rutin. In the present study, we examined the possibility of interaction between human ATP-binding cassette (ABC) transporter ABCB1 and four guanidine alkaloids isolated from P. nitens (i.e., galegine, nitensidine A, pterogynidine, and pterogynine) using human T cell lymphoblast-like leukemia cell line CCRF-CEM and its multi-drug resistant (MDR) counterpart CEM/ADR5000. In XTT assays, CEM/ADR5000 cells were resistant to the four guanidine alkaloids compared to CCRF-CEM cells, although the four guanidine alkaloids exhibi…

ATP Binding Cassette Transporter Subfamily BLeukemia T-CellStereochemistryATPasePharmaceutical ScienceATP-binding cassette transporterGuanidineschemistry.chemical_compoundStructure-Activity RelationshipCell Line TumorDrug DiscoveryHumansheterocyclic compoundsBinding siteGuanidineCytotoxicityP-glycoproteinPharmacologyAdenosine TriphosphatasesbiologyPlant ExtractsAlkaloidFabaceaeFluoresceinsAntineoplastic Agents PhytogenicDrug Resistance MultipleMolecular Docking SimulationComplementary and alternative medicinechemistryBiochemistryVerapamilDrug Resistance Neoplasmbiology.proteinMonoterpenesMolecular MedicineATP-Binding Cassette TransportersKaempferolPhytotherapyPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Intraoperative transfusion practices in Europe

2016

PubMed: 26787795

AUSTRIAN BENCHMARKMaleBlood transfusionmedicine.medical_treatment610 Medizinanaemia anesthesia blood transfusion surgery transfusion trigger030204 cardiovascular system & hematologyGUIDELINESsurgeryCohort Studies0302 clinical medicine030202 anesthesiologyMedicine and Health SciencesMedicineProspective StudiesProspective cohort studyddc:610Research Support Non-U.S. Gov'tMiddle AgedHospitalsEuropeFemaleAllogeneic transfusionCohort studymedicine.medical_specialtyTransfusion rateObservational Studyanesthesiablood transfusionELECTIVE SURGERYClinical Practice03 medical and health sciencesJournal Articleanaemia ; anesthesia ; blood transfusion ; surgery ; transfusion triggerHumansBlood TransfusionElective surgeryCHLC ANSIntensive care medicineanaemiatransfusion triggerIntraoperative Carebusiness.industryPREOPERATIVE ANEMIAPATIENT BLOOD MANAGEMENTClinical trialAnesthesiology and Pain MedicineEmergency medicinebusinessPacked red blood cellsREQUIREMENTSBritish journal of anaesthesia
researchProduct

Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome

2020

Background: Familial chylomicronemia syndrome (FCS) is characterized by severe fasting hypertriglyceridemia, abdominal pain, and recurrent acute pancreatitis. Available triglyceride-lowering drugs are insufficient to avoid pancreatitis. Therefore, there is a significant unmet medical need for effective triglyceride-lowering drugs for patients with FCS. Case report: We report the second case of a patient with FCS and recurrent pancreatitis treated with lomitapide. Lomitapide treatment resulted in a reduction of fasting TG levels from 2897 mg/dL (32.71 mmol/L) to an average of 954 mg/dL (10.77 mmol/L) on the 30 mg lomitapide equating to a 67% reduction from baseline. After 26 months of lomita…

Abdominal painPediatricsmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyRecurrent pancreatitisInternal medicineFatty liverHumansMedicineProspective Studiesmedicine.diagnostic_testbusiness.industryFatty liverHypertriglyceridemiaFCSFamilial Chylomicronemiamedicine.diseaseLomitapideLomitapideAcute pancreatitisPancreatitischemistry030220 oncology & carcinogenesisLiver biopsyAcute DiseaseAcute pancreatitisPancreatitisBenzimidazolesHyperlipoproteinemia Type Ilipids (amino acids peptides and proteins)medicine.symptomCardiology and Cardiovascular MedicinebusinessFamilial chylomicronaemia syndromeAtherosclerosis
researchProduct

An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma

2020

Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL). Targeted approaches (i.e. ibrutinib, bortezomib, and lenalidomide) represent the backbone of therapy for relapsed cases. Areas covered: Acalabrutinib is a novel small molecule with a butynamide moiety specifically designed to irreversibly inhibit Bruton tyrosine kinase (BTK), which is more potent and selective than ibrutinib. Relevant publications have been identified through literature searches using the terms 'mantle cell lymphoma' and 'acalabrutinib'. Expert opinion: Aca…

Acalabrutinib; BTK; MCL; therapy; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Lymphoma Mantle-Cell; Protein Kinase Inhibitors; PyrazinesOncologymedicine.medical_specialtyLymphomaAntineoplastic AgentsLymphoma Mantle-Cell03 medical and health scienceschemistry.chemical_compound0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsAgammaglobulinaemia Tyrosine KinaseHumansMedicineBruton's tyrosine kinasePharmacology (medical)Protein Kinase InhibitorsLenalidomidePharmacologytherapy.therapybiologyAcalabrutinibbusiness.industryBortezomibStandard treatmentMCLGeneral MedicineMantle-Cellmedicine.diseaseClinical trialchemistryBTKPyrazines030220 oncology & carcinogenesisIbrutinibBenzamidesbiology.proteinAcalabrutinibMantle cell lymphomabusiness030217 neurology & neurosurgerymedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

Hemophilia Clinical Consults: Epidemiology, Clinical Course, and Management of Acquired Hemophilia A

2011

Acquired Haemophilia
researchProduct

Acquired haemophilia A: a case repor

2009

Acquired haemophilia A
researchProduct

Resection of Presacral Mass in Currarino Syndrome is Mandatory

2018

IF 2.646; International audience

Acute Lymphoblastic leukemia[SDV.CAN] Life Sciences [q-bio]/Cancer[SDV.CAN]Life Sciences [q-bio]/CancerHaematology
researchProduct

Acute Nonlymphocytic Leukemia in Adults: Pathophysiology, Status of Current Therapy, and New Approaches

1987

Recent information concerning the cell biology of leukemias has provided new insights into the pathophysiology and pathogenesis of acute leukemia, involving the detection of leukemia viruses, oncogenes and their products, and the discovery of factors supporting clonal leukemic growth. Murine, avian, and cat leukemia viruses are well characterized. To date, only HTLV I appears to be a likely candidate as a human leukemia virus. For both avian and murine viruses, there is a fundamental classification distinction between long-latency viruses (LLV) and acute transforming viruses (ATV). The ATV are replication defective and must be propagated with a helper virus. They have within their genome an…

Acute leukemiaHaematopoiesisLeukemiaAcute myeloblastic leukemiaHelper virusmedicineHairy cell leukemiaBiologymedicine.diseaseVirologyVirusLong terminal repeat
researchProduct

Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER…

2021

Abstract Aims In this secondary analysis of the VOYAGER trial, rivaroxaban 2.5 mg twice/day plus aspirin 100 mg/day was assessed in older adults. Advanced age is associated with elevated bleeding risk and unfavourable net benefit for dual antiplatelet therapy in chronic coronary artery disease. The risk–benefit of low-dose rivaroxaban in patients ≥75 years with peripheral artery disease (PAD) after lower extremity revascularization (LER) has not been described. Methods and results The primary endpoint was a composite of acute limb ischaemia, major amputation, myocardial infarction, ischaemic stroke, or cardiovascular death. The principal safety outcome was thrombolysis in myocardial infarct…

Acute limb ischaemiamedicine.medical_specialtyBrain IschemiaPeripheral Arterial DiseaseRivaroxabanInternal medicineClinical endpointHumansMedicineMyocardial infarctionAgedRivaroxabanAspirinbusiness.industryAbsolute risk reductionNumber needed to harmmedicine.diseaseStrokeCardiologyNumber needed to treatDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsTIMIFactor Xa Inhibitorsmedicine.drugEuropean Heart Journal
researchProduct